<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease - Tam, KW - 2018 | Cochrane Library</title> <meta content="Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease - Tam, KW - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011353.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease - Tam, KW - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011353.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011353.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease" name="citation_title"/> <meta content="Ka‐Wai Tam" name="citation_author"/> <meta content="Mei‐Yi Wu" name="citation_author"/> <meta content="e220121@gmail.com" name="citation_author_email"/> <meta content="Fahad Javaid Siddiqui" name="citation_author"/> <meta content="Edwin SY Chan" name="citation_author"/> <meta content="Singapore Clinical Research Institute" name="citation_author_institution"/> <meta content="Yanan Zhu" name="citation_author"/> <meta content="A*STAR" name="citation_author_institution"/> <meta content="Tazeen H Jafar" name="citation_author"/> <meta content="Duke NUS Graduate Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD011353.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/11/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011353.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011353.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011353.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Renal Dialysis [adverse effects, mortality]; *Vascular Access Devices; Arteriovenous Shunt, Surgical [*methods]; Fatty Acids, Omega‐3 [*administration &amp; dosage, adverse effects]; Graft Occlusion, Vascular [complications, epidemiology, *prevention &amp; control]; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic [*therapy]; Thrombosis [*prevention &amp; control]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011353.pub2&amp;doi=10.1002/14651858.CD011353.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011353\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011353\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ja","pl","fr","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011353.pub2",title:"Omega\\u20103 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease",firstPublishedDate:"Nov 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011353.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011353.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011353.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011353.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011353.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011353.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011353.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011353.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011353.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011353.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4757 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011353.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/appendices#CD011353-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/table_n/CD011353StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/table_n/CD011353StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#CD011353-cr-0002">Ka‐Wai Tam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#CD011353-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Mei‐Yi Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#CD011353-cr-0004">Fahad Javaid Siddiqui</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#CD011353-cr-0005">Edwin SY Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#CD011353-cr-0006">Yanan Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information#CD011353-cr-0007">Tazeen H Jafar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information/en#CD011353-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 November 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011353.pub2">https://doi.org/10.1002/14651858.CD011353.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011353-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011353-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011353-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011353-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011353-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011353-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011353-abs-0001" lang="en"> <section id="CD011353-sec-0001"> <h3 class="title" id="CD011353-sec-0001">Background</h3> <p>Maintaining long‐term vascular access patency is necessary for high quality haemodialysis (HD) treatment of patients with the terminal and most serious stage of chronic kidney disease (CKD) ‐ end‐stage kidney disease (ESKD). Oral supplementation with omega‐3 fatty acids (ω‐3FA) may help to prevent blockage of the vascular access by reducing the risk of thrombosis and stenosis. </p> </section> <section id="CD011353-sec-0002"> <h3 class="title" id="CD011353-sec-0002">Objectives</h3> <p>To evaluate the efficacy and safety of ω‐3FA supplementation versus placebo or no treatment for maintaining vascular access patency in ESKD patients undergoing HD. </p> </section> <section id="CD011353-sec-0003"> <h3 class="title" id="CD011353-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 23 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. </p> </section> <section id="CD011353-sec-0004"> <h3 class="title" id="CD011353-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of omega‐3 fatty acids versus placebo that assessed the patency of arteriovenous fistula (AVF) or arteriovenous graft (AVG) types of vascular access in ESKD patients. </p> </section> <section id="CD011353-sec-0005"> <h3 class="title" id="CD011353-sec-0005">Data collection and analysis</h3> <p>We assessed the risk of bias of each eligible study using the Cochrane Risk of Bias tool and made separate overall risk of bias judgments for the efficacy and safety outcomes. The certainty of evidence was assessed using the GRADE approach. The primary efficacy outcome was loss of vascular patency and the primary safety outcomes were occurrences of serious adverse events (e.g. death, hospitalisation, cardiovascular events, major bleeding). Secondary outcomes were the occurrence of non‐serious adverse events (e.g. minor bleeding, gastrointestinal events and other adverse events). Efficacy effects were reported as risk ratios (RR) and safety effects as risk differences (RD) with 95% confidence intervals (CI). Studies were pooled separately by type of vascular access using a random‐effects model. </p> </section> <section id="CD011353-sec-0006"> <h3 class="title" id="CD011353-sec-0006">Main results</h3> <p>Five studies (833 participants) were included; one was a very small pilot study of 7 participants. All studies compared oral ω‐3FA supplements against placebo. Four studies enrolled participants with arteriovenous grafts (AVGs), and the other had participants with arteriovenous fistulas (AVFs). The risk of bias for both efficacy and safety outcomes was unclear for all studies, due mainly to incomplete reporting for allocation concealment and incompleteness of study follow‐up. </p> <p>In AVF patients, ω‐3FA supplementation probably makes little or no difference to the 12‐month risk of patency loss (1 study, 536 participants: RR 1.01, 95% CI 0.84 to 1.21; moderate certainty evidence), risk of death (1 study, 567 participants: RD 0.00, 95% CI ‐0.03 to 0.02; moderate certainty evidence) and risk of hospitalisation (1 study, 567 participants: RD 0.00, 95% CI ‐0.08 to 0.08; low certainty evidence). There was no information on cardiovascular events and major bleeding. </p> <p>In AVG patients, it is very uncertain whether ω‐3FA supplementation reduces the risk of patency loss within 6 months (2 studies, 41 participants: RR 0.91, 95% CI 0.36 to 2.28; very low certainty evidence) or 12 months (2 studies, 220 participants: RR 0.59, 95% CI 0.27 to 1.31; very low certainty evidence). ω‐3FA supplementation may make little or no difference to the risk of death within 6 to 12 months in AVG patients (4 studies, 261 participants: RD 0.01, 95% CI ‐0.05 to 0.07; low certainty evidence). It is very uncertain if ω‐3FA supplementation increases the risk of hospitalisation (3 studies, 65 participants: RD 0.08, 95% CI ‐0.11 to 0.28; very low certainty evidence), changes the risk of cardiovascular events (4 studies, 261 participants: RD ‐0.02, 95% CI ‐0.11 to 0.07; very low certainty evidence), or increases the risk of major bleeding (3 studies, 65 participants: RD 0.08, 95% CI ‐0.11 to 0.28; very low certainty evidence) within 6 to 12 months in AVG patients. There may be an increase in the risk of mild gastrointestinal adverse reactions (3 studies, 65 participants: RD 0.25, 95% CI 0.07 to 0.43; low certainty evidence) such as a sensation of bloatedness, gas or a fishy aftertaste. </p> </section> <section id="CD011353-sec-0007"> <h3 class="title" id="CD011353-sec-0007">Authors' conclusions</h3> <p>In CKD patients with an AVF, there is moderate certainty that ω‐3FA supplementation makes little or no difference to preventing patency loss; and in patients with an AVG, it is very uncertain that ω‐3FA supplementation prevents patency loss within 12 months. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011353-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011353-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011353-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011353-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011353-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011353-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011353-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011353-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011353-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011353-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011353-abs-0005" lang="en"> <h3>Fish oil for preventing blockage of haemodialysis vascular access in patients with kidney failure </h3> <p><b>What is the issue?</b> </p> <p>Patients requiring long‐term haemodialysis (HD) because of poorly functioning kidneys need a reliable and efficient method of circulating blood at high flow rates between their bodies and the HD machine. Arteriovenous fistulas (AVFs) and grafts (AVGs) are the two main methods of achieving such long‐term vascular access. An AVF is a surgically constructed direct connection (fistula) between a patient's artery and vein. An AVG is a synthetic flexible hollow tubing (graft) that indirectly connects a patient's artery and vein and is usually used when a fistula cannot be created. During HD, the fistula or graft is pierced by needles (cannulated) connected to the dialysis machine. The patency of these artificial connections may be blocked by blood clots (thrombosis) or by a narrowing (stenosis) of the vein. The risk of this occurring is lower for AVFs, making it the method of choice. When a blockage does occur, HD cannot be performed and surgical or radiological salvage procedures will be urgently required. Omega‐3 fatty acid fish oils can reduce blood viscosity and might conceivably reduce the risk of blood clots and blood vessel narrowing, hence improving long‐term vascular access and quality of HD. </p> <p><b>What did we do?</b> </p> <p>We collected data from studies that tested HD patients with supplements of omega‐3 fatty acid fish oils against placebo and that reported results for preventing vascular access blockage and for the following side‐effects ‐ death, hospitalisation, cardiovascular events, major bleeding, minor bleeding, gastrointestinal events, and other adverse events. We analysed and reported the results separately for patients with AVFs and AVGs. </p> <p><b>What did we find?</b> </p> <p>We found five randomised controlled trials (RCTs) that studied a total of 833 participants; one was a very small pilot study of seven participants. Four studies involved patients with AVGs; there was only one study of AVFs. The outcomes were measured over a period of six or 12 months. There were reservations about the overall quality of all the studies, making us moderately to highly uncertain about the evidence. In AVF patients, we are moderately certain that fish oil supplements do not prevent blockage nor do they cause additional harm but the evidence only comes from one study. In AVG patients, we are very uncertain of the evidence for preventing blockage or causing serious harm, but there may be an increased risk of mild digestive side‐effects such as a sensation of bloatedness, gas or a fishy aftertaste. </p> <p><b>Conclusions</b> </p> <p>There is limited high quality data on the benefits of omega‐3 fish oil supplementation for preventing HD blockage in kidney failure patients. We did not find strong evidence that omega‐3 fish oil supplements could prevent blockage of HD vascular access or that it increases the risk of serious and non‐serious side‐effects. All the evidence for preventing blockages come from just one or two studies, so more and better quality studies are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011353-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011353-sec-0111"></div> <h3 class="title" id="CD011353-sec-0112">Implications for practice</h3> <section id="CD011353-sec-0112"> <p>There is no strong evidence that ω‐3FA fish oil supplements reduces the risk of AVF or AVG access blockage in patients not currently consuming it. There is also no strong evidence of an increased risk in serious adverse effects; however there may be a moderately increased risk of bloatedness, gas or a fishy aftertaste. So for those currently consuming it, the decision to continue or not will also involve other considerations specific to the individual patient such as the tolerability of specific side‐effects, the recurring cost of medication and the burden of polypharmacy. </p> </section> <h3 class="title" id="CD011353-sec-0113">Implications for research</h3> <section id="CD011353-sec-0113"> <p>In AVF patients, since the evidence comes from a single study that was flawed in important ways (e.g. change of primary outcome definition, large attrition rate, and early study termination), coupled with the importance of this mode of vascular access, further studies are recommended. </p> <p>In AVG patients, there is a tantalizing but very weak signal of effect, again this comes from primarily one study. Since AVGs are at a higher risk of blockage than AVFs, and they continue to have an important role either as a first‐line or second‐line access, further studies are recommended. </p> <p>In addition, future studies should consider (1) recruiting a more real‐world population not specially selected for being at low bleeding risk, (2) stratified randomisation for suspected effect‐modifiers, (3) use of an active anti‐thrombotic control group, (4) standardized outcome definition and criteria of assessment, (5) follow‐up of at least one year, and (6) systematic reporting of adverse events and reasons for losses to follow‐up. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011353-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011353-sec-0029"></div> <div class="table" id="CD011353-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Dialysis vascular access outcomes in AVF patients with ESKD<br/> <b>Setting:</b> chronic outpatient haemodialysis<br/> <b>Intervention:</b> omega‐3 fatty acids (ω‐3FA)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ω‐3FA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of patency: assessed with clinical absence of bruit or need of rescue intervention<br/> Follow up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>475 per 1,000<br/> (395 to 569) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.84 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: death<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000<br/> (2 to 52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.00<br/> (‐0.03 to 0.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>567 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: hospitalisation<br/> Follow up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1,000<br/> (305 to 465) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.00<br/> (‐0.08 to 0.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>567 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events: cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events: major bleeding</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RD:</b> Risk difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> 95% CI is wide and consistent with both important harm or benefit </p> <p><sup>2</sup> Unclear risk of bias ‐ attrition bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011353-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> dialysis vascular access outcomes in AVG patients with ESKD<br/> <b>Setting:</b> chronic outpatient haemodialysis<br/> <b>Intervention:</b> omega‐3 fatty acids (ω‐3FA)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ω‐3FA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Loss of patency by 6 months assessed with Fistulagram or duplex ultrasonography<br/> Follow up: range 6 to 8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.91<br/> (0.36 to 2.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>41 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1,000<br/> (144 to 912) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1,000<br/> (126 to 798) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>607 per 1,000<br/> (240 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Loss of patency by 12 months assessed with angiography<br/> Follow up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.59<br/> (0.27 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>220 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>633 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>373 per 1,000<br/> (171 to 829) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>366 per 1,000<br/> (167 to 812) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1,000<br/> (203 to 983) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Serious adverse events: death<br/> Follow up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD 0.01<br/> (‐0.05 to 0.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>261 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/> (12 to 132) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1,000<br/> (0 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (32 to 152) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events: hospitalisation<br/> Follow up: mean 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RD 0.08<br/> (‐0.11 to 0.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000<br/> (0 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Serious adverse events: cardiovascular events<br/> Follow up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD ‐0.02<br/> (‐0.11 to 0.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>261 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1,000<br/> (60 to 240) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1,000<br/> (65 to 245) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: major bleeding<br/> Follow up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000<br/> (0 to 280) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.08<br/> (‐0.11 to 0.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RD:</b> Risk difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear risk of bias ‐ selection and attrition bias </p> <p><sup>2</sup> Point estimates favour different interventions </p> <p><sup>3</sup> 95% CI is wide and consistent with both important harm and benefit </p> <p><sup>4</sup> Point estimates are widely differing and I<sup>2</sup> &gt; 50% </p> <p><sup>5</sup> 95% CI is wide and consistent with both moderate harm and benefit </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011353-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011353-sec-0030"></div> <section id="CD011353-sec-0031"> <h3 class="title" id="CD011353-sec-0031">Description of the condition</h3> <p>Patients with end‐stage kidney disease (ESKD) on long‐term haemodialysis (HD) require either an arteriovenous fistula (AVF) or an arteriovenous graft (AVG) to provide long‐term vascular access to and from the dialysis machine. While central venous catheters are commonly inserted when urgent vascular access is required, they are associated with high rates of infection and stenosis. An AVF is a deliberate connection between an artery and a vein constructed from an end‐to‐side vein to artery anastomosis, typically in the forearm or upper arm. An AVG is a synthetic graft (generally made of expanded polytetrafluoroethylene) interposed between an artery and a vein. From 1996 to 2007, AVF use rose from 24% to 47% and increased further to 63% by 2010 in the USA (<a href="./references#CD011353-bbs2-0015" title="EthierJ , MendelssohnDC , ElderSJ , HasegawaT , AkizawaT , AkibaT , et al. Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study. Nephrology Dialysis Transplantation2008;23(10):3219–26. [MEDLINE: 18511606] ">Ethier 2008</a>; <a href="./references#CD011353-bbs2-0034" title="PisoniRL , ZepelL , PortFK , RobinsonBM . Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. American Journal of Kidney Diseases2015;65(6):905‐15. [MEDLINE: 25662834] ">Pisoni 2015</a>). Moreover, AVG use fell by 50% in the USA from 58% in 1996 to 28% by 2007 (<a href="./references#CD011353-bbs2-0015" title="EthierJ , MendelssohnDC , ElderSJ , HasegawaT , AkizawaT , AkibaT , et al. Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study. Nephrology Dialysis Transplantation2008;23(10):3219–26. [MEDLINE: 18511606] ">Ethier 2008</a>). An AVF is generally preferred over an AVG because of the higher chance of long‐term patency, but the drawback is a longer waiting time from construction to first‐use (maturation) and a higher maturation failure rate (<a href="./references#CD011353-bbs2-0020" title="HayashiR , HuangE , NissensonAR . Vascular access for hemodialysis. Nature Clinical Practice Nephrology2006;2(9):504‐13. [MEDLINE: 16941043] ">Hayashi 2006</a>). AVGs can be cannulated within 2 to 6 weeks, in contrast the median time to cannulate AVFs in the USA and UK is 3 months, and in Japan it is 30 days (<a href="./references#CD011353-bbs2-0035" title="RavaniP , BrunoriG , MandolfoS , CancariniG , ImbasciatiE , MarcelliD , et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. Journal of the American Society of Nephrology2004;15(1):204‐9. [MEDLINE: 14694174] ">Ravani 2004</a>). Hence AVG placement remains an important alternative for patients (i) requiring early vascular access, (ii) with small or weak veins, or (iii) whose AVF have failed to mature (<a href="./references#CD011353-bbs2-0025" title="LeeHW , AllonM . When should a patient receive an arteriovenous graft rather than a fistula?. Seminars in Dialysis2013;26(1):6‐10. [MEDLINE: 23173947] ">Lee 2013</a>). However, AVG patency declines at a faster rate becoming worse than AVF in the long term (<a href="./references#CD011353-bbs2-0031" title="MundaR , FirstMR , AlexanderJW , LinnemannCCJr , FidlerJP , KitturD . Polytetrafluoroethylene graft survival in hemodialysis. JAMA1983;249(2):219‐22. [MEDLINE: 6848807] ">Munda 1983</a>). </p> <p>Problems of establishing and maintaining a vascular access (e.g. maturation failure, infection, stenosis, thrombosis, aneurysm, limb ischaemia) accounts for much of the mortality, morbidity and diminished dialysis quality in patients receiving HD (<a href="./references#CD011353-bbs2-0013" title="AnnukM , ZilmerM , LindL , LindeT , FellstromB . Oxidative stress and endothelial function in chronic renal failure. Journal of the American Society of Nephrology2001;12(12):2747‐52. [MEDLINE: 11729244] ">Annuk 2001</a>; <a href="./references#CD011353-bbs2-0026" title="LocatelliF , CanaudB . Dialysis adequacy today: a European perspective. Nephrology Dialysis Transplantation2012;27(8):3043‐8. [MEDLINE: 22743335] ">Locatelli 2012</a>; <a href="./references#CD011353-bbs2-0036" title="Roy‐ChaudhuryP , KellyBS , NarayanaA , DesaiP , MelhemM , MundaR , et al. Hemodialysis vascular access dysfunction from basic biology to clinical intervention. Advances in Renal Replacement Therapy2002;9(2):74‐84. [MEDLINE: 12085383] ">Roy‐Chaudhury 2002</a>). Vascular access dysfunction results in frequent hospitalisation for salvage surgical or endovascular operations (<a href="./references#CD011353-bbs2-0017" title="FeldmanHI , HeldPJ , HutchinsonJT , StoiberE , HartiganMF , BerlinJA . Hemodialysis vascular access morbidity in the United States. Kidney International1993;43(5):1091‐6. [MEDLINE: 8510387] ">Feldman 1993</a>). Because the number of patients needing HD is increasing, the burden of complications due to vascular access and related hospitalisation is expected to rise. Therefore therapies to prevent vascular access dysfunction are of significant interest. </p> <p>Several strategies have specifically targeted prolonging vascular access patency by preventing stenosis and thrombosis, including advanced pre‐operative planning, newer graft materials and design and use of specific drugs with anticoagulant, antiplatelet, or vascular‐remodelling properties (<a href="./references#CD011353-bbs2-0024" title="HungYN , KoPJ , NgYY , WuSC . The longevity of arteriovenous graft for hemodialysis patients‐‐externally supported or nonsupported. Clinical Journal of The American Society of Nephrology: CJASN2010;5(6):1029‐35. [MEDLINE: 20378642] ">Hung 2010</a>; <a href="./references#CD011353-bbs2-0029" title="MihmanliI , BesirliK , KurugogluS , AtakirK , HaiderS , OgutG , et al. Cephalic vein and hemodialysis fistula: surgeon's observation versus color Doppler ultrasonographic findings. Journal of Ultrasound in Medicine2001;20(3):217‐22. [MEDLINE: 11270525] ">Mihmanli 2001</a>; <a href="./references#CD011353-bbs2-0037" title="SaranR , DykstraDM , WolfeRA , GillespieB , HeldPJ , YoungEW , et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases2002;40(6):1255‐63. [MEDLINE: 12460045] ">Saran 2002</a>). In his review of the role of ω‐3FAs in the treatment of kidney disease, <a href="./references#CD011353-bbs2-0016" title="FassettRG , GobeGC , PeakeJM , CoombesJS . Omega‐3 polyunsaturated fatty acids in the treatment of kidney disease. American Journal of Kidney Diseases2010;56(4):728‐42. [MEDLINE: 20493605] ">Fassett 2010</a> reviews evidence for several biochemical and physiological effects that suggest that fish oil may also be useful for preventing vascular access failure. </p> </section> <section id="CD011353-sec-0032"> <h3 class="title" id="CD011353-sec-0032">Description of the intervention</h3> <p>Omega‐3 fatty acids (ω‐3FA) are polyunsaturated fatty acids that are essential dietary nutrients as the human body cannot synthesize it <i>de novo</i>. There are three major forms, alpha‐linolenic acid is found in plants such as nuts and seeds, the other two forms ‐ eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are found in marine sources such as algae, phytoplankton and fish. In this review only the EPA and DHA forms of ω‐3FAs were evaluated in the included studies, so we use the term "fish oil" interchangeably with ω‐3FA to refer to the intervention. </p> </section> <section id="CD011353-sec-0033"> <h3 class="title" id="CD011353-sec-0033">How the intervention might work</h3> <p>Damage to the endothelial cells due to shear stress from turbulent blood flow or mechanical trauma from external compression, repeated venipunctures and angioplasties are thought to be the main reasons leading to smooth muscle proliferation, neointimal hyperplasia and stenosis, which in turn increases the risk of thrombosis (<a href="./references#CD011353-bbs2-0028" title="MacRaeJM , DipchandC , OliverM , MoistL , LokC , ClarkE , et al. Arteriovenous access failure, stenosis, and thrombosis. Canadian Journal of Kidney Health &amp; Disease2016;3(1):2054358116669126. [MEDLINE: 28270918] ">MacRae 2016</a>). There are <i>in vitro</i> kidney tissue studies and <i>in vivo</i> kidney disease model studies that demonstrate ω‐3FA could disrupt this pathogenic sequence by its anti‐inflammatory and antithrombotic effects (<a href="./references#CD011353-bbs2-0016" title="FassettRG , GobeGC , PeakeJM , CoombesJS . Omega‐3 polyunsaturated fatty acids in the treatment of kidney disease. American Journal of Kidney Diseases2010;56(4):728‐42. [MEDLINE: 20493605] ">Fassett 2010</a>), inhibitory effects on smooth muscle proliferation, platelet aggregation, polypeptide growth factors, cytokine release and positive haemodynamic effects on blood viscosity and red blood cell flexibility (<a href="./references#CD011353-bbs2-0014" title="CahillPD , SarrisGE , CooperAD , WoodPD , KosekJC , MitchellRS , et al. Inhibition of vein graft intimal thickening by eicosapentanoic acid: reduced thromboxane production without change in lipoprotein levels or low‐density lipoprotein receptor density. Journal of Vascular Surgery1988;7(1):108‐18. [MEDLINE: 3336117] ">Cahill 1988</a>; <a href="./references#CD011353-bbs2-0018" title="FriedmanA , MoeS . Review of the effects of omega‐3 supplementation in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2006;1(2):182‐92. [MEDLINE: 17699207] ">Friedman 2006</a>; <a href="./references#CD011353-bbs2-0027" title="Lorente‐CebriánS , CostaAG , Navas‐CarreteroS , ZabalaM , MartínezJA , Moreno‐AliagaMJ . Role of omega‐3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. Journal of Physiology &amp; Biochemistry2013;69(3):633‐51. [MEDLINE: 23794360] ">Lorente‐Cebrián 2013</a>; <a href="./references#CD011353-bbs2-0030" title="MozaffarianD , WuJH . Omega‐3 fatty acids and cardiovascular disease effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology2011;58(20):2047‐67. [MEDLINE: 22051327] ">Mozaffarian 2011</a>). </p> </section> <section id="CD011353-sec-0034"> <h3 class="title" id="CD011353-sec-0034">Why it is important to do this review</h3> <p>The high prevalence of ESKD means that maintenance of adequate vascular access will become a significant burden for many individuals and clinicians. Vascular access failure is associated with increased morbidity and mortality, therefore an effective way to prevent it is important. This review summarises the evidence for benefit and harm of ω‐3FA supplementation in ESKD patients undergoing HD. Another Cochrane review has reviewed the evidence of adjuvant medical therapy in ESKD patients with HD (<a href="./references#CD011353-bbs2-0040" title="TannerNC , DaSilvaA . Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD002786.pub3] ">Tanner 2015</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011353-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011353-sec-0035"></div> <p>To evaluate the efficacy and safety of ω‐3FA supplementation versus placebo or no treatment for maintaining vascular access patency in ESKD patients undergoing HD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011353-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011353-sec-0036"></div> <section id="CD011353-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011353-sec-0038"> <h4 class="title">Types of studies</h4> <p>All parallel group randomised controlled trials (RCTs) comparing any dose or form of ω‐3FAs compared to placebo or no treatment in ESKD patients. </p> </section> <section id="CD011353-sec-0039"> <h4 class="title">Types of participants</h4> <section id="CD011353-sec-0040"> <h5 class="title">Inclusion criteria</h5> <p> <ol id="CD011353-list-0001"> <li> <p>Adult patients (aged ≥ 18 years) currently on HD or in whom HD was planned to start within 6 months because of stage 4 or 5 chronic kidney disease (CKD) </p> </li> <li> <p>An existing or planned first or subsequent vascular access (either AVF or AVG) in the upper or lower arm </p> </li> <li> <p>Not experiencing an early loss of vascular access patency due to technical reasons.</p> </li> </ol> </p> </section> <section id="CD011353-sec-0041"> <h5 class="title">Exclusion criteria</h5> <p>Patients requiring HD because of an acute kidney injury.</p> </section> </section> <section id="CD011353-sec-0042"> <h4 class="title">Types of interventions</h4> <section id="CD011353-sec-0043"> <h5 class="title">Experimental intervention</h5> <p>Any form or dose of ω‐3FA given by any route with intervention starting immediately or shortly after creation of the vascular access. </p> </section> <section id="CD011353-sec-0044"> <h5 class="title">Control intervention</h5> <p>Placebo or no intervention.</p> </section> </section> <section id="CD011353-sec-0045"> <h4 class="title">Types of outcome measures</h4> <section id="CD011353-sec-0046"> <h5 class="title">Primary outcomes</h5> <section id="CD011353-sec-0047"> <h6 class="title">Loss of patency</h6> <p>The primary efficacy outcome was loss of patency (inability to use the vascular access without salvage radiological or surgical intervention to restore patency) measured either as a dichotomous outcome occurring between 3 to 12 months or as a time‐to‐event outcome. Early loss of patency due to technical reasons was excluded. </p> </section> <section id="CD011353-sec-0048"> <h6 class="title">Serious adverse events</h6> <p>The primary safety outcome was occurrence of any serious adverse event such as death, hospitalisation, major bleeding (e.g. haemorrhage requiring hospital admission or transfusion), cardiovascular event or other life‐threatening or severely disabling event. </p> </section> </section> <section id="CD011353-sec-0049"> <h5 class="title">Secondary outcomes</h5> <section id="CD011353-sec-0050"> <h6 class="title">Non‐serious adverse events</h6> <p>Non‐life‐threatening adverse events such as minor bleeding, gastrointestinal symptoms, or infection. </p> </section> </section> </section> </section> <section id="CD011353-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011353-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> up to 23 July 2018 through the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from several sources. </p> <p> <ol id="CD011353-list-0002"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD011353-sec-0117">Appendix 1</a> for search terms used in this review. </p> </section> <section id="CD011353-sec-0053"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD011353-list-0003"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Contact with investigators known to be involved in previous studies seeking information about unpublished or ongoing studies. </p> </li> </ol> </p> </section> </section> <section id="CD011353-sec-0054"> <h3 class="title" id="CD011353-sec-0054">Data collection and analysis</h3> <section id="CD011353-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Titles and abstracts were screened independently by two authors, who also independently assessed the retrieved full text for inclusion. </p> </section> <section id="CD011353-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by three authors using a standard data extraction template. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. When relevant data was only published in earlier versions, these data were used. Any disagreements were resolved by consensus involving all authors. </p> </section> <section id="CD011353-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following domains were independently assessed by three authors using the Cochrane Risk of Bias assessment tool (<a href="./references#CD011353-bbs2-0023" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<i>see</i><a href="./appendices#CD011353-sec-0118">Appendix 2</a>). </p> <p> <ul id="CD011353-list-0004"> <li> <p>Adequacy of sequence generation (selection bias)</p> </li> <li> <p>Adequacy of allocation concealment (selection bias)</p> </li> <li> <p>Adequacy of blinding of participants and care‐givers (performance bias)</p> </li> <li> <p>Adequacy of blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incompleteness of outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other bias</p> <ul id="CD011353-list-0005"> <li> <p>inappropriate per protocol analysis</p> </li> <li> <p>potential inappropriate influence from commercial sponsors</p> </li> </ul> </li> </ul> </p> <p>Separate risk of bias judgments were made for the efficacy outcome (loss of patency) and the safety outcomes (serious adverse events, non‐serious adverse events). These judgments were used in the assessment of the Risk of Bias domain for the GRADE Certainty of Evidence rating. </p> </section> <section id="CD011353-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>The effect for loss of patency was expressed as a risk ratio (RR). Due to the presence of no events in both treatment arms of one study, the safety outcomes (serious adverse events and adverse events) were expressed as risk differences (RD) with 95% confidence intervals (CI) so that this study could be included in the meta‐analyses. Where time‐to‐ event data (e.g. time to loss of patency) was reported, the effect was expressed as a hazard ratio (HR). </p> </section> <section id="CD011353-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The study participant was the unit of analysis. If multiple‐arm studies were identified, all comparisons relevant to the review would be included. If the same control group was the common comparator in several intervention‐control comparisons (e.g. a single placebo arm with two or more different ω‐3FA arms), care would be taken not to double‐count its outcomes should a meta‐analysis be done. </p> </section> <section id="CD011353-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>Wherever possible, the original authors were contacted for missing data. When attrition caused missing outcome data, various alternative intention‐to‐treat analysis (ITT) scenarios were performed (<a href="#CD011353-tbl-0003">Table 1</a>) and one of these was adopted as the default analysis for this review (see <a href="#CD011353-tbl-0004">Table 2</a>). </p> <div class="table" id="CD011353-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Intention‐to‐treat (ITT) case scenarios</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>ITT Scenario</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Losses to follow‐up assumed to have events<sup>1</sup> of interest</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ω‐3FA Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control Group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>In this review, all outcome events were bad events e.g. loss of patency, serious adverse events, non‐serious adverse events </p> </div> </div> <div class="table" id="CD011353-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intention‐to‐treat (ITT) case scenarios used in the analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Default ITT scenario used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analyses</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 2<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All except <a href="./references#CD011353-fig-0006" title="">Analysis 1.4</a> and <a href="./references#CD011353-fig-0008" title="">Analysis 1.6</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one scenario needed<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-fig-0006" title="">Analysis 1.4</a> (death); <a href="./references#CD011353-fig-0008" title="">Analysis 1.6</a> (cardiovascular event) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All except <a href="./references#CD011353-fig-0004" title="">Analysis 1.2</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Authors' modified ITT analysis<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-fig-0004" title="">Analysis 1.2</a> (loss of patency) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Middle‐case 2 scenario used because the middle‐case 1 scenario was identical with the best‐case scenario. </p> <p><sup>2</sup>No ITT scenario analysis was required as there was complete follow‐up and ascertainment for these two outcomes. </p> <p><sup>3</sup>Authors performed a modified ITT analysis on 536 out of 567 randomised participants, that involved imputing values for the primary outcome of AVF failure for 122 "missing data" see <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> Fig 1 and Table 2. </p> </div> </div> <p><a href="#CD011353-tbl-0005">Table 3</a> describes the manner in which serious adverse events and adverse events outcome data were extracted or imputed in several ambiguous circumstances. </p> <div class="table" id="CD011353-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reporting and extraction of AE data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of serious adverse events/adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Manner of reporting in paper</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>How outcome data values were inferred for extraction and analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0006"> <li> <p>"One EPA patient died within 1 week of initiation of the study from an acute myocardial infarction." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </li> <li> <p>See Figure 1 of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0007"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no deaths occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have died</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0008"> <li> <p>"One patient receiving EPA developed a gastrointestinal bleed requiring hospitalization." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0009"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no hospitalisation occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0010"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have been hospitalised</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0011"> <li> <p>"The occurrences of minor and major bleeding episodes, changes in lipid status and blood pressure, hospitalizations for cardiovascular events, and death were determined. All endpoints reported were prespecified." </p> </li> </ul> <ul id="CD011353-list-0012"> <li> <p>"There was no difference in bleeding (9 events in the fish oil group vs 8 in the placebo group; P&gt;99) or other significant clinical adverse events between the 2 treatment groups." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Cardiovascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0013"> <li> <p>"One EPA patient died within 1 week of initiation of the study from an acute myocardial infarction." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> </p> </li> <li> <p>See Table 2 of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0014"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no cardiovascular events occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0015"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have experienced a cardiovascular event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> <p> <ul id="CD011353-list-0016"> <li> <p>"Secondary outcomes included components of the primary outcome, and safety outcomes."</p> </li> </ul> <ul id="CD011353-list-0017"> <li> <p>"Adverse drug events, including bleeding events (16 [6%] vs 10 [4%]; P = .23) and gastrointestinal adverse effects (15 [5%] vs 14 [5%]; P = .86), were similar for the fish oil and placebo groups. Death occurred in 8 participants allocated to fish oil and 9 allocated to placebo (Table 3)." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis. Although it might be reasonable to assume there were no events there was too much missing data (&gt; 20% in each arm) for any ITT scenario analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0018"> <li> <p>"One patient receiving EPA developed a gastrointestinal bleed requiring hospitalization." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>"No overt bleeding episodes were observed in either group." (<a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0019"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no major bleeding occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0020"> <li> <p>"There was no difference in bleeding (9 events in the fish oil group vs 8 in the placebo group; P&gt;.99)..." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from default meta‐analysis, as bleeding events were aggregated and not separately reported as major or minor </p> <p>Sensitivity analysis done included the study by assuming all were major bleeding events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis. Although it might be reasonable to assume there were no events (see Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) there was too much missing data (&gt; 20% in each arm) for any ITT scenario analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Minor bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0021"> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct. We assumed that all the bleeding events were minor as they were not listed under the serious adverse events category </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0022"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our ITT analysis assumed no minor bleeding occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> <p> <ul id="CD011353-list-0023"> <li> <p>"One EPA patient died within 1 week of initiation of the study from an acute myocardial infarction. One patient receiving EPA developed a gastrointestinal bleed requiring hospitalization. One patient receiving placebo developed gas gangrene secondary to Clostridium perfringens which required debridement and antibiotics." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As there were only seven participants, ITT analysis assumed complete reporting of all adverse events i.e. no minor bleeding events except for the one imputed for the scenario </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0024"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this individual to have experienced a minor bleed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0025"> <li> <p>"There was no difference in bleeding (9 events in the fish oil group vs 8 in the placebo group; P&gt;.99)..." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from default meta‐analysis, as bleeding events were aggregated and not separately reported as major or minor </p> <p>Sensitivity analysis done included the study by assuming all were minor bleeding events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Gastrointestinal events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0026"> <li> <p>"A total of 5 patients in the treatment group (n‐3) and 2 in the control</p> </li> <li> <p>group (n‐6) reported gastrointestinal distress that included bloating, gas, and a “fish” aftertaste." (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007)</a> </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As there were only seven participants, ITT analysis assumed complete reporting of all adverse events i.e. no gastrointestinal events except for the one imputed for the scenario analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0027"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have experienced a gastrointestinal event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0028"> <li> <p>"There was no difference in bleeding... or other significant clinical adverse events between the 2 treatment groups." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Other adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0029"> <li> <p>"One patient receiving placebo developed gas gangrene secondary to Clostridium perfringens which required debridement and antibiotics." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0030"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no other adverse events occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0031"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have experienced some other adverse events.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </div> </section> <section id="CD011353-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical and design heterogeneity were described in the <a href="./references#CD011353-sec-0127" title="">Characteristics of included studies</a> and "Risk of bias" Tables. These were used to guide the decision to pool the data. Heterogeneity was quantified by the I<sup>2</sup> test (<a href="./references#CD011353-bbs2-0022" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>) and incorporated in the assessment of the Inconsistency domain for the GRADE certainty of evidence rating. </p> </section> <section id="CD011353-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>Vulnerability to reporting bias was indirectly assessed by documenting funding sources in the "Other bias" domain of the Risk of bias tables. We did not present funnel plots as any pattern would have been uninterpretable because we could not be certain that no other biases (no other than publication bias) were influencing the pattern and because there were insufficient number of studies to reliably define a pattern (<a href="./references#CD011353-bbs2-0023" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>With regard to serious adverse events and adverse events, when any of our pre‐specified adverse outcomes had not been explicitly reported (either as having or not having occurred) in the study report, we assumed that no events had occurred provided there was evidence of reporting of other serious adverse events and adverse events. We reasoned that current ethical trial conduct would require investigators to monitor for any adverse events and that a non‐mention could be taken as equivalent to a non‐occurrence. We only had to make this assumption for one study (<a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> (see <a href="#CD011353-tbl-0005">Table 3</a>). </p> </section> <section id="CD011353-sec-0063"> <h4 class="title">Data synthesis</h4> <p>Pooled effects were separately estimated for AVF and AVG access types and pooling was done using the random‐effects model. </p> </section> <section id="CD011353-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If data were available, we planned subgroup analyses to explore differences in treatment effectiveness (effect modification) by possible sources of heterogeneity such as patient characteristics (age, gender, comorbidities, smoking status), underlying renal pathology, location of vascular access (e.g. forearm, upper arm) and intervention dose. </p> <p>Due to the lack of appropriate data these analyses were not performed.</p> </section> <section id="CD011353-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the effect of assumptions about missing or ambiguous outcome data and its analysis (ITT analysis case scenarios, per‐protocol analysis (<a href="#CD011353-tbl-0003">Table 1</a>)) on the robustness of the respective meta‐analyses. The ITT "middle‐case 1" or "middle‐case 2" scenarios for the individual study results were used for most of the meta‐analyses (see <a href="#CD011353-tbl-0004">Table 2</a>). The middle‐case 1 scenario was the default scenario unless it was identical with the best‐case scenario, in that situation the middle‐case 2 scenario was used instead. For the <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> study, we used the author's modified ITT imputation analysis of the loss of patency outcome. </p> <section id="CD011353-sec-0066"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the clinically important outcomes in two 'Summary of findings' (SoF) tables (<a href="./references#CD011353-bbs2-0038" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>) ‐ one for AVFs and the other for AVGs. The SoF tables also include a rating of the "Certainty of Evidence" for each outcome using the GRADE approach (<a href="./references#CD011353-bbs2-0019" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The certainty of evidence is the extent to which one can be confident that the estimate of effect or association is close to the truth. It involves consideration of (GRADE) risk of bias (i.e. Cochrane overall risk of bias taken across studies), directness of evidence, heterogeneity of effects, precision of effect estimates and risk of publication bias (<a href="./references#CD011353-bbs2-0039" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). The certainty of evidence was rated for the following five outcomes: </p> <p> <ul id="CD011353-list-0032"> <li> <p>Loss of patency by 6 to 12 months</p> </li> <li> <p>Death</p> </li> <li> <p>Hospitalisation</p> </li> <li> <p>Cardiovascular events</p> </li> <li> <p>Major bleeding</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011353-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011353-sec-0067"></div> <section id="CD011353-sec-0068"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011353-sec-0127" title="">Characteristics of included studies</a>; <a href="./references#CD011353-sec-0128" title="">Characteristics of excluded studies</a> </p> <section id="CD011353-sec-0069"> <h4 class="title">Results of the search</h4> <p>Our search of the Cochrane Kidney and Transplant's Specialised Register identified 36 records. Full‐text assessment of these records resulted in the inclusion of five eligible studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>). Seven studies were excluded (<a href="./references#CD011353-bbs2-0006" title="BowdenRG , WilsonRL , DeikeE , GentileM . Fish oil supplementation lowers C‐reactive protein levels independent of triglyceride reduction in patients with end‐stage renal disease. Nutrition in Clinical Practice2009;24(4):508‐12. [MEDLINE: 19461006] ">Bowden 2009</a>; <a href="./references#CD011353-bbs2-0007" title="deFijterCW , Popp‐SnijdersC , OeLP , TranDD , van derMeulenJ , DonkerAJ . Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?. Haematologica1995;80(4):332‐4. [MEDLINE: 7590502] ">De Fijter 1995</a>; <a href="./references#CD011353-bbs2-0008" title="DonnellySM , AliMA , ChurchillDN . Effect of n‐3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. Journal of the American Society of Nephrology1992;2(11):1634‐9. [MEDLINE: 1610984] ">Donnelly 1992a</a>; <a href="./references#CD011353-bbs2-0009" title="Dashti‐KhavidakiS , GharekhaniA , KhatamiMR , MiriES , KhaliliH , RazeghiE , et al. Effects of omega‐3 fatty acids on depression and quality of life in maintenance hemodialysis patients. American Journal of Therapeutics2014;21(4):275‐87. [MEDLINE: 24987942] GharekhaniA , Dashti‐KhavidakiS , Lessan‐PezeshkiM , KhatamiMR . Potential effects of omega‐3 fatty acids on insulin resistance and lipid profile in maintenance hemodialysis patients: a randomized placebo‐controlled trial. Iranian Journal of Kidney Diseases2016;10(5):310‐8. [MEDLINE: 27721230] GharekhaniA , KhatamiM , Dashti‐KhavidakiS , RazeghiE , AbdollahiA , Hashemi‐NazariS , et al. Potential effects of omega‐3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. DARU: Journal of Pharmaceutical Sciences2014;22(1):11. [EMBASE: 2014129171] GharekhaniA , KhatamiMR , Dashti‐KhavidakiS , RazeghiE , AbdollahiA , Hashemi‐NazariSS , et al. Effects of oral supplementation with omega‐3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients. Journal of Renal Nutrition2014;24(3):177‐85. [MEDLINE: 24613294] GharekhaniA , KhatamiMR , Dashti‐KhavidakiS , RazeghiE , NoorbalaAA , Hashemi‐NazariSS , et al. The effect of omega‐3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo‐controlled clinical trial. European Journal of Clinical Pharmacology2014;70(6):655‐65. [MEDLINE: 24643636] ">Gharekhani 2014</a>; <a href="./references#CD011353-bbs2-0010" title="DegerSM , HungAM , EllisCD , BookerC , BianA , ChenG , et al. High dose omega‐3 fatty acid administration and skeletal muscle protein turnover in maintenance hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2016;11(7):1227‐35. [MEDLINE: 27281699] HungAM , BookerC , EllisCD , SiewED , GravesAJ , ShintaniA , et al. Omega‐3 fatty acids inhibit the up‐regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrology Dialysis Transplantation2015;30(2):266‐74. [MEDLINE: 25204316] ">Hung 2015</a>; <a href="./references#CD011353-bbs2-0011" title="SaifullahA , MoeSM , SahaC , LiY , WatkinsBA , FriedmanAN . Oral fish oil supplementation is efficacious in chronic hemodialysis patients: a pilot study [abstract no: 183]. American Journal of Kidney Diseases2007;49(4):A70. [CENTRAL: CN‐00794891] SaifullahA , WatkinsBA , SahaC , LiY , MoeSM , FriedmanAN . Oral fish oil supplementation raises blood omega‐3 levels and lowers C‐reactive protein in haemodialysis patients‐‐a pilot study. Nephrology Dialysis Transplantation2007;22(12):3561‐7. [MEDLINE: 17623719] ">Saifullah 2007</a>; <a href="./references#CD011353-bbs2-0012" title="TumlinJ , RobertsB , CrymesJ , WheelerA , SomerenJ , HalkarR . Eicosapentanoic acid (EPA fish oil) reduces platelet deposition in dialyis AV grafts: a randomized, double‐blind, placebo‐controlled trial [abstract no: SA‐FC167]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):137P. [CENTRAL: CN‐00448075] ">Tumlin 2002a</a>). <a href="#CD011353-fig-0001">Figure 1</a> depicts the study inclusion and exclusion process. </p> <div class="figure" id="CD011353-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011353-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011353-sec-0070"> <h4 class="title">Included studies</h4> <p>Five studies (833 participants) evaluating efficacy and safety of ω‐3FA were included (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>), see <a href="./references#CD011353-sec-0127" title="">Characteristics of included studies</a>. The studies were published between 1990 and 2017, and had sample sizes ranging from 7 to 567. One was a very small "preliminary pilot study" (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) that recruited participants at high‐risk of AVG patency failure (history of 3 or more thromboses in the past 12 months). The largest study (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) was also the only one to recruit AVF participants (stage 4 or 5 CKD, primary <i>de novo</i> vascular access). <a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> recruited participants with newly placed AVGs, while <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> and <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> involved both "first access" and "subsequent access" participants. Four studies excluded participants at high risk of bleeding (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>). </p> <p>All studies evaluated either a combination of DHA‐EPA (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>) or EPA alone (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) as the ω‐3FA fish oil supplement. Treatment was initiated at a range of different times ‐ the day before scheduled AVF placement (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>), at the start of dialysis (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>), seven days after AVG placement (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>) and within two weeks of AVG placement (<a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>). Treatment duration was only clearly reported by three studies ‐ <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> (6 months), <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> (12 weeks) and <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> (12 months). Dosages ranged from 3 to 6 g/day. Four studies described methods to assess compliance ‐ three used lipid analysis of cell or platelet membranes (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>) and one used dietician‐support and pill counting (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007)</a>. </p> <p>All studies reported some version of vascular access failure as their primary outcome.</p> <p> <ul id="CD011353-list-0033"> <li> <p>Thrombosis or stenosis &gt; 50% requiring salvage angioplasty at 6 months (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>) </p> </li> <li> <p>Outflow stenosis by duplex ultrasound at 6 months (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>Thrombosis or stenosis requiring salvage at 12 months (<a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>) </p> </li> <li> <p>Thrombosis, access abandonment or cannulation failure at 12 months (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) </p> </li> <li> <p>Thrombosis at 12 months (<a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>). </p> </li> </ul> </p> <p>Results for the following serious adverse events could be directly extracted or reasonably inferred from what was reported (see <a href="#CD011353-tbl-0005">Table 3</a>). </p> <p> <ul id="CD011353-list-0034"> <li> <p>Death: five studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> </p> </li> <li> <p>Hospitalisation: four studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> </p> </li> <li> <p>Cardiovascular events: four studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> e.g. stroke, peripheral vascular disease, myocardial infarction, congestive heart‐failure, cardiac‐related death </p> </li> <li> <p>Major bleeding: three studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) e.g. gastrointestinal bleeding requiring hospitalisation. </p> </li> </ul> </p> <p>Results for the following non‐serious adverse events could be directly extracted or reasonably inferred from what was reported (see <a href="#CD011353-tbl-0005">Table 3</a>). </p> <p> <ul id="CD011353-list-0035"> <li> <p>Minor bleeding: four studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) </p> </li> <li> <p>Gastrointestinal events: four studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> e.g. bloating, gas, "fish" aftertaste </p> </li> <li> <p>Other adverse events: four studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a>. </p> </li> </ul> </p> </section> <section id="CD011353-sec-0071"> <h4 class="title">Excluded studies</h4> <p>Seven studies were excluded (see <a href="./references#CD011353-sec-0128" title="">Characteristics of excluded studies</a>). Six studies included no primary outcomes of interest (<a href="./references#CD011353-bbs2-0006" title="BowdenRG , WilsonRL , DeikeE , GentileM . Fish oil supplementation lowers C‐reactive protein levels independent of triglyceride reduction in patients with end‐stage renal disease. Nutrition in Clinical Practice2009;24(4):508‐12. [MEDLINE: 19461006] ">Bowden 2009</a>; <a href="./references#CD011353-bbs2-0008" title="DonnellySM , AliMA , ChurchillDN . Effect of n‐3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. Journal of the American Society of Nephrology1992;2(11):1634‐9. [MEDLINE: 1610984] ">Donnelly 1992a</a>; <a href="./references#CD011353-bbs2-0009" title="Dashti‐KhavidakiS , GharekhaniA , KhatamiMR , MiriES , KhaliliH , RazeghiE , et al. Effects of omega‐3 fatty acids on depression and quality of life in maintenance hemodialysis patients. American Journal of Therapeutics2014;21(4):275‐87. [MEDLINE: 24987942] GharekhaniA , Dashti‐KhavidakiS , Lessan‐PezeshkiM , KhatamiMR . Potential effects of omega‐3 fatty acids on insulin resistance and lipid profile in maintenance hemodialysis patients: a randomized placebo‐controlled trial. Iranian Journal of Kidney Diseases2016;10(5):310‐8. [MEDLINE: 27721230] GharekhaniA , KhatamiM , Dashti‐KhavidakiS , RazeghiE , AbdollahiA , Hashemi‐NazariS , et al. Potential effects of omega‐3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. DARU: Journal of Pharmaceutical Sciences2014;22(1):11. [EMBASE: 2014129171] GharekhaniA , KhatamiMR , Dashti‐KhavidakiS , RazeghiE , AbdollahiA , Hashemi‐NazariSS , et al. Effects of oral supplementation with omega‐3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients. Journal of Renal Nutrition2014;24(3):177‐85. [MEDLINE: 24613294] GharekhaniA , KhatamiMR , Dashti‐KhavidakiS , RazeghiE , NoorbalaAA , Hashemi‐NazariSS , et al. The effect of omega‐3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo‐controlled clinical trial. European Journal of Clinical Pharmacology2014;70(6):655‐65. [MEDLINE: 24643636] ">Gharekhani 2014</a>; <a href="./references#CD011353-bbs2-0010" title="DegerSM , HungAM , EllisCD , BookerC , BianA , ChenG , et al. High dose omega‐3 fatty acid administration and skeletal muscle protein turnover in maintenance hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2016;11(7):1227‐35. [MEDLINE: 27281699] HungAM , BookerC , EllisCD , SiewED , GravesAJ , ShintaniA , et al. Omega‐3 fatty acids inhibit the up‐regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrology Dialysis Transplantation2015;30(2):266‐74. [MEDLINE: 25204316] ">Hung 2015</a>; <a href="./references#CD011353-bbs2-0011" title="SaifullahA , MoeSM , SahaC , LiY , WatkinsBA , FriedmanAN . Oral fish oil supplementation is efficacious in chronic hemodialysis patients: a pilot study [abstract no: 183]. American Journal of Kidney Diseases2007;49(4):A70. [CENTRAL: CN‐00794891] SaifullahA , WatkinsBA , SahaC , LiY , MoeSM , FriedmanAN . Oral fish oil supplementation raises blood omega‐3 levels and lowers C‐reactive protein in haemodialysis patients‐‐a pilot study. Nephrology Dialysis Transplantation2007;22(12):3561‐7. [MEDLINE: 17623719] ">Saifullah 2007</a>; <a href="./references#CD011353-bbs2-0012" title="TumlinJ , RobertsB , CrymesJ , WheelerA , SomerenJ , HalkarR . Eicosapentanoic acid (EPA fish oil) reduces platelet deposition in dialyis AV grafts: a randomized, double‐blind, placebo‐controlled trial [abstract no: SA‐FC167]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):137P. [CENTRAL: CN‐00448075] ">Tumlin 2002a</a>) and one study was a cross‐over study (<a href="./references#CD011353-bbs2-0007" title="deFijterCW , Popp‐SnijdersC , OeLP , TranDD , van derMeulenJ , DonkerAJ . Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?. Haematologica1995;80(4):332‐4. [MEDLINE: 7590502] ">De Fijter 1995</a>). </p> </section> </section> <section id="CD011353-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias is summarised in <a href="#CD011353-fig-0002">Figure 2</a> and in the <a href="./references#CD011353-sec-0127" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD011353-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011353-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011353-sec-0073"> <h4 class="title">Allocation</h4> <p><b>Random sequence generation</b> </p> <p>Random sequence generation was judged as low risk in three studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>), all documented computer‐generated randomisation. Although described as randomised, <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> was judged as having unclear risk because the randomisation method was not reported. </p> <p><b>Allocation concealment</b> </p> <p>Allocation concealment was judged as low risk in two studies (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>), which reported central, independent randomisation facilities. The other studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>) were judged as unclear risk because they did not report the method. </p> </section> <section id="CD011353-sec-0074"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel (performance bias) and blinding of outcome assessors (detection bias) were judged as low risk in all studies due to the use of placebo controls and the objective nature of the outcome measurements. </p> </section> <section id="CD011353-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Loss to follow‐up and analysis drop‐out rates in the other four studies ranged from 0% to 25% in the fish oil group and 0% to 11.8% in the placebo group (see <a href="#CD011353-tbl-0006">Table 4</a>; <a href="#CD011353-tbl-0007">Table 5</a>; <a href="#CD011353-tbl-0008">Table 6</a>; <a href="#CD011353-tbl-0009">Table 7</a>; <a href="#CD011353-tbl-0010">Table 8</a>). These were comparable or greater than the outcome event risks observed, so for all outcomes, all studies were judged as unclear risk because the effect estimates could be sensitive to assumptions made about the outcome status of the drop‐outs i.e. the method of missing data analysis. </p> <div class="table" id="CD011353-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study drop‐outs and analysis totals (Bowden 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drop‐outs from authors' analysis (see </b><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] "><b>Bowden 2007</b> </a><b> Table 1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for analysis drop‐out</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (14 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"In all, 2 patients from the placebo group and 3 patients from the n‐3 group completed the study but were not included in the analysis because of noncompliance..." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (15 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT‐ intention‐to‐treat</p> </div> </div> <div class="table" id="CD011353-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study drop‐outs and analysis totals (Diskin 1990)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss to follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for loss to follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"One EPA patient died within 1 week of initiation of the study</p> <p>from an acute myocardial infarction."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </div> <div class="table" id="CD011353-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Study drop‐outs and analysis totals (FAVOURED 2009)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drop‐outs from authors' analysis (see </b><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] "><b>FAVOURED 2009</b> </a><b> Table 2 and 3)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for analysis drop‐outs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcomes: 14 (270 participants analysed)</p> <p>Safety outcomes: 0 (284 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcome: 270</p> <p>Safety outcomes: 284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>See <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> Fig 1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcomes: 17 (266 participants analysed)</p> <p>Safety outcomes: 0 (283 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcome: 266</p> <p>Safety outcomes: 283</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </div> <div class="table" id="CD011353-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Study drop‐outs and analysis totals (FISH 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drop‐outs from authors' analysis (see </b><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. "><b>FISH 2007</b> </a><b> Figure 1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for analysis drop‐outs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (99 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>See <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> Fig 1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (97 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </div> <div class="table" id="CD011353-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Study drop‐outs and analysis totals (Schmitz 2002)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss to follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for loss to follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </div> </section> <section id="CD011353-sec-0076"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was judged as low risk in three studies (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>), where pre‐specified outcomes of interest to this review were all reported. Two studies were judged as unclear risk of bias ‐ <a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> did not report the efficacy outcomes for five patients who completed follow‐up but were deemed as non‐compliant and also only reported adverse events judged as related to ω‐3FA supplementation, and <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> did not report hospitalisation events and also did not differentiate between major and minor bleeding events. We performed a sensitivity analysis with <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> by assuming all the bleeding events reported were either major or minor bleeds. </p> </section> <section id="CD011353-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>Two other potential sources of bias were considered ‐ the funding source and the method of imputing missing outcome data. Three studies were judged as unclear risk of bias: two studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) did not report their funding sources; one study (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) did not provide the method of imputation for missing outcome data and it had a pharmaceutical industry funder for the ω‐3FA supplement. No other potential sources of bias were identified in two studies (<a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>). </p> </section> </section> <section id="CD011353-sec-0078"> <h3 class="title" id="CD011353-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD011353-tbl-0001"><b>Summary of findings for the main comparison</b> Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD</a>; <a href="./full#CD011353-tbl-0002"><b>Summary of findings 2</b> Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD</a> </p> <p>The effects of fish oil are reported separately for AVF and AVG studies. As the risk of patency loss is known to differ between AVFs and AVGs, the effectiveness of fish oil could also differ between them. See <a href="./full#CD011353-tbl-0001">summary of findings Table for the main comparison</a> for the effects in AVF patients and <a href="./full#CD011353-tbl-0002">summary of findings Table 2</a> for the effects in AVG patients. </p> <section id="CD011353-sec-0079"> <h4 class="title">AVF</h4> <section id="CD011353-sec-0080"> <h5 class="title">Primary outcomes</h5> <section id="CD011353-sec-0081"> <h6 class="title">Loss of patency by 12 months</h6> <p>ω‐3FA probably makes little or no difference to the risk of loss pf patency within 12 months in AVF patients (<a href="./references#CD011353-fig-0004" title="">Analysis 1.2</a>.1 (1 study, 536 participants): RR 1.01, 95% CI 0.84 to 1.21; moderate certainty evidence). </p> </section> <section id="CD011353-sec-0082"> <h6 class="title">Serious adverse events</h6> <section id="CD011353-sec-0083"> <p><b>Death</b></p> <p>ω‐3FA probably makes little or no difference to the risk of death within 12 months in AVF patients (<a href="./references#CD011353-fig-0006" title="">Analysis 1.4</a>.1 (1 study, 567 participants): RD 0.00, 95% CI ‐0.03 to 0.02; moderate certainty evidence). </p> </section> <section id="CD011353-sec-0084"> <p><b>Hospitalisation</b></p> <p>ω‐3FA may make little or no difference to the risk of hospitalisation within 12 months in AVF patients (<a href="./references#CD011353-fig-0007" title="">Analysis 1.5</a>.1 (1 study, 567 participants): RD 0.00, 95% CI ‐0.08 to 0.08; low certainty evidence). </p> </section> <section id="CD011353-sec-0085"> <p><b>Cardiovascular events and major bleeding</b></p> <p>Cardiovascular events and major bleeding were not reported.</p> </section> </section> </section> <section id="CD011353-sec-0086"> <h5 class="title">Secondary outcomes</h5> <section id="CD011353-sec-0087"> <h6 class="title">Non‐serious adverse events</h6> <section id="CD011353-sec-0088"> <p><b>Minor bleeding</b></p> <p>ω‐3FA probably makes little or no difference to the risk of minor bleeding within 12 months in AVF patients (<a href="./references#CD011353-fig-0010" title="">Analysis 1.8</a>.1 (1 study, 567 participants): RD 0.02, 95% CI ‐0.01 to 0.06; moderate certainty evidence). </p> </section> <section id="CD011353-sec-0089"> <p><b>Gastrointestinal events</b></p> <p>ω‐3FA probably makes little or no difference to the risk of gastrointestinal events within 12 months in AVF patients (<a href="./references#CD011353-fig-0011" title="">Analysis 1.9</a>.1 (1 study, 567 participants): RD 0.00, 95% CI ‐0.03 to 0.04; moderate certainty evidence). </p> </section> <section id="CD011353-sec-0090"> <p><b>Other adverse events</b></p> <p>ω‐3FA probably makes little or no difference to the risk of other adverse events within 12 months in AVF patients (<a href="./references#CD011353-fig-0012" title="">Analysis 1.10</a>.1 (1 study, 567 participants): RD 0.01, 95% CI ‐0.02 to 0.03; moderate certainty evidence). </p> </section> </section> </section> </section> <section id="CD011353-sec-0091"> <h4 class="title">AVG</h4> <section id="CD011353-sec-0092"> <h5 class="title">Primary outcomes</h5> <section id="CD011353-sec-0093"> <h6 class="title">Loss of patency by 6 months</h6> <p>It is very uncertain whether ω‐3FA slightly reduces the risk of loss of patency within 6 months in AVG patients (<a href="./references#CD011353-fig-0003" title="">Analysis 1.1</a> (2 studies, 41 participants): RR 0.91, 95% CI 0.36 to 2.28; very low certainty evidence). </p> <p> <ul id="CD011353-list-0036"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0013" title="">Analysis 1.11</a>. The pooled scenario RRs range from 0.61 (in favour of ω‐3FA) to 1.02. The two middle case scenarios have RRs of 0.66 and 0.95. There is a moderate degree of heterogeneity in any particular scenario (I<sup>2</sup> from 30% to 52%); the point estimates of the two studies in the meta‐analysis are highly discordant. If the pilot study (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) is excluded, four of the five point estimates in the scenario analysis favour placebo, so evidence for direction of effect is highly sensitive to inclusion of the pilot study. </p> </li> </ul> </p> </section> <section id="CD011353-sec-0094"> <h6 class="title">Loss of patency by 12 months</h6> <p>It is very uncertain whether ω‐3FA reduces the risk of loss of patency within 12 months in AVG patients (<a href="./references#CD011353-fig-0004" title="">Analysis 1.2</a>.2 (2 studies, 220 participants): RR 0.59, 95% CI 0.27 to 1.31; very low certainty evidence). </p> <p> <ul id="CD011353-list-0037"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0014" title="">Analysis 1.12</a>. The pooled scenario RRs range from 0.45 to 0.66, all in favour of ω‐3FA. The two middle case scenarios have RRs of 0.49 and 0.60. There is a moderate to high degree of heterogeneity in any particular scenario (I<sup>2</sup> from 58% to 79%); the point estimates of the two studies in the meta‐analysis are highly discordant. </p> </li> </ul> </p> </section> <section id="CD011353-sec-0095"> <h6 class="title">Serious adverse events</h6> <section id="CD011353-sec-0096"> <p><b>Death</b></p> <p>ω‐3FA may make little or no difference to the risk of death within 6 to 12 months in AVG patients (<a href="./references#CD011353-fig-0006" title="">Analysis 1.4</a>.2 (4 studies, 261 participants): RD 0.01, 95% CI ‐0.05 to 0.07; low certainty evidence). </p> <p> <ul id="CD011353-list-0038"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0015" title="">Analysis 1.13</a>. The pooled scenario RDs range from ‐0.03 to 0.10. The two middle case scenarios have RDs of 0 and 0.03. There is a very low degree of heterogeneity in any particular scenario (I<sup>2</sup> close to 0%). </p> </li> </ul> </p> </section> <section id="CD011353-sec-0097"> <p><b>Hospitalisation</b></p> <p>It is very uncertain whether ω‐3FA increases the risk of hospitalisation within 6 months to 12 months in AVG patients (<a href="./references#CD011353-fig-0007" title="">Analysis 1.5</a>.2 (3 studies, 65 participants): RD 0.08, 95% CI ‐0.11 to 0.28; very low certainty evidence). </p> <p> <ul id="CD011353-list-0039"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0016" title="">Analysis 1.14</a>. The pooled scenario RDs range from ‐0.03 to 0.01. The two middle case scenarios have RDs of 0.01 and 0.11. There is a low degree of heterogeneity in any particular scenario (I<sup>2</sup> from 0% to 10%). If the pilot study was excluded, the risk of hospitalisation changes to little or no difference (RD 0.02, 95% CI ‐0.08 to 0.11); the 95% CI is consistent with both moderate harm and benefit. </p> </li> </ul> </p> </section> <section id="CD011353-sec-0098"> <p><b>Cardiovascular events</b></p> <p>It is very uncertain whether ω‐3FA increases or decreases the risk of cardiovascular events within 6 to 12 months in AVG patients (<a href="./references#CD011353-fig-0008" title="">Analysis 1.6</a> (four studies, 261 participants): RD ‐0.02, 95% CI ‐0.11 to 0.07; very low certainty evidence). </p> <p> <ul id="CD011353-list-0040"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0017" title="">Analysis 1.15</a>. The pooled scenario RDs range from ‐0.09 to 0.10. The two middle case scenarios have RDs of ‐0.03 and 0.01. There is a low to high degree of heterogeneity in any particular scenario (I<sup>2</sup> from 0% to 73%). </p> </li> </ul> </p> </section> <section id="CD011353-sec-0099"> <p><b>Major bleeding</b></p> <p>It is very uncertain whether ω‐3FA increases the risk of major bleeding within 6 to 12 months in AVG patients (<a href="./references#CD011353-fig-0009" title="">Analysis 1.7</a> (3 studies, 65 participants): RD 0.08, 95% CI ‐0.11 to 0.28; very low certainty evidence). </p> <p> <ul id="CD011353-list-0041"> <li> <p>Sensitivity analysis 1: See <a href="./references#CD011353-fig-0018" title="">Analysis 1.16</a>. The pooled scenario RDs range from ‐0.03 to 0.16. The two middle case scenarios have RDs of 0.01 and 0.11. There is a low degree of heterogeneity in any particular scenario (I<sup>2</sup> from 0% to 10%). If the pilot study was excluded, the risk of major bleeding reduces to little or no difference (RD 0.02, 95% CI ‐0.08 to 0.11); the 95% CI is consistent with both moderate harm and benefit. </p> </li> <li> <p>Sensitivity analysis 2: See <a href="./references#CD011353-fig-0009" title="">Analysis 1.7</a>. After inclusion of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> by assuming all the reported bleeding events were major, the estimate of effect reduces to little or no difference (RD 0.02, 95% CI ‐0.05 to 0.10); the 95% CI is consistent with both moderate important harm and benefit. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011353-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD011353-sec-0101"> <h6 class="title">Non‐serious adverse events</h6> <section id="CD011353-sec-0102"> <p><b>Minor bleeding</b></p> <p>ω‐3FA may slightly increase the risk of minor bleeding within 6 to 12 months in AVG patients (<a href="./references#CD011353-fig-0010" title="">Analysis 1.8</a>.2 (3 studies, 65 participants): RD 0.03, 95% CI ‐0.07 to 0.12; low certainty evidence). </p> <p> <ul id="CD011353-list-0042"> <li> <p>Sensitivity analysis 1: See <a href="./references#CD011353-fig-0019" title="">Analysis 1.17</a>. The pooled scenario RDs range from ‐0.05 to 0.14. The two middle case scenarios have RDs of 0 and 0.09. There is a very low degree of heterogeneity in any particular scenario (I<sup>2</sup> close to 0%). </p> </li> <li> <p>Sensitivity analysis 2: See <a href="./references#CD011353-fig-0010" title="">Analysis 1.8</a>. After inclusion of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> by assuming all the reported bleeding events were minor, there is little impact on the estimate of effect (RD 0.02, 95% CI ‐0.04 to 0.08). </p> </li> </ul> </p> </section> <section id="CD011353-sec-0103"> <p><b>Gastrointestinal events</b></p> <p>ω‐3FA may increase the risk of gastrointestinal events within 6 to 12 months in AVG patients (<a href="./references#CD011353-fig-0011" title="">Analysis 1.9</a>.2 (3 studies, 65 participants): RD 0.25, 95% CI 0.07 to 0.43; low certainty evidence). </p> <p> <ul id="CD011353-list-0043"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0020" title="">Analysis 1.18</a>. The pooled scenario RDs range from 0.14 to 0.33. The two middle case scenarios have RDs of 0.18 and 0.28. There is a very low degree of heterogeneity in any particular scenario (I<sup>2</sup> close to 0%). </p> </li> </ul> </p> </section> <section id="CD011353-sec-0104"> <p><b>Other adverse events</b></p> <p>ω‐3FA may make little or no difference to the risk of other adverse events within 6 to 12 months in AVG patients (<a href="./references#CD011353-fig-0012" title="">Analysis 1.10</a>.2 (3 studies, 65 participants): RD 0.02, 95% CI ‐0.08 to 0.11; low certainty evidence). </p> <p> <ul id="CD011353-list-0044"> <li> <p>Sensitivity analysis: See <a href="./references#CD011353-fig-0021" title="">Analysis 1.19</a>. The pooled scenario RDs range from ‐0.07 to 0.12. The two middle case scenarios have RDs of ‐0.01 and 0.09. There is a low degree of heterogeneity in any particular scenario (I<sup>2</sup> from 0% to 18%). </p> </li> </ul> </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011353-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011353-sec-0105"></div> <section id="CD011353-sec-0106"> <h3 class="title" id="CD011353-sec-0106">Summary of main results</h3> <p>There is little evidence that ω‐3FA fish oil supplementation can prevent blockage (patency loss) of HD vascular access compared to no supplementation. For AVF access, we are moderately certain that ω‐3FAs make little or no difference to preventing patency loss within 12 months. This result is based on one large multicentre study that was terminated early (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>). For AVG patency loss at both 6 and 12 months of follow‐up, the best effect estimates are in favour of ω‐3FA but with very low certainty and so despite the apparently sizable relative risk reduction the 95% CIs indicates that the intervention might make little or no difference. </p> <p>There is little evidence that ω‐3FA fish oil supplementation increases the risk of some serious adverse events compared to no supplementation. For AVF access, ω‐3FA fish oil supplementation probably makes little or no difference to the risk of death (moderate certainty) or hospitalisation (low certainty). This result is based on one large multicentre study that was terminated early. There is no evidence from these studies on the risk of cardiovascular events or major bleeding. For AVG access, the certainty of evidence for increased serious adverse events risks is low or very low. ω‐3FA fish oil supplementation may make little or no difference to the risk of death and cardiovascular events. The observed increased risks of hospitalisation and major bleeding are very uncertain results skewed by the single small pilot study of seven participants (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>). The 95% CIs indicate the intervention might make little or no difference. In a sensitivity analysis with <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> excluded, there is little or no difference in the risk of hospitalisation or major bleeding. Of the non‐serious adverse events, there may be an increased risk of minor gastrointestinal side‐effects such as sensations of bloatedness, gas and a fishy aftertaste. </p> </section> <section id="CD011353-sec-0107"> <h3 class="title" id="CD011353-sec-0107">Overall completeness and applicability of evidence</h3> <p>This review gives a comprehensive review of the current best RCT evidence for the effect of omega‐3 fish oil supplements for preventing HD vascular access blockage and for affecting the risk of serious and non‐serious side‐effects in CKD patients. Overall the evidence is limited as there are only five studies, one of which is a very small pilot study. Only polytetrafluoroethylene grafts were used, there were no studies of newer graft designs and materials. The longest follow‐up time was one year. There is even more limited evidence and hence applicability to the following patient categories: </p> <p> <ul id="CD011353-list-0045"> <li> <p>Patients with AVF access ‐ only one study (<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) of patients with AVFs that terminated early with a large proportion (23%) of missing data requiring imputation </p> </li> <li> <p>Patients with a history of vascular access failure ‐ only one very small pilot study (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> </p> </li> <li> <p>Patients not at low risk of bleeding ‐ only one very small pilot study (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> </p> </li> <li> <p>Patients with other potential effect modifiers (e.g. elderly, diabetics, smokers) ‐ non‐randomised analysis reported in one study ([<a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) </p> </li> </ul> </p> </section> <section id="CD011353-sec-0108"> <h3 class="title" id="CD011353-sec-0108">Quality of the evidence</h3> <p>No study had a low overall risk of bias for either the efficacy or safety outcomes. Randomisation method but not allocation concealment was generally well reported. Blinding was convincing due to the employment of placebo supplements. Attrition bias due to a high proportion of losses to follow‐up relative to the outcome event rate were of concern in all studies, and selective reporting of adverse events was a concern in two studies. Evidence for AVF patients comes from only a single study that terminated early with a large proportion of missing data (22.8%) requiring imputation in a modified ITT analysis. Another potential bias of concern was the non‐declaration of the study funder. </p> </section> <section id="CD011353-sec-0109"> <h3 class="title" id="CD011353-sec-0109">Potential biases in the review process</h3> <p>We have not identified any major bias in our review process. Our literature search included several international databases and search criteria were intentionally broadened to identify as many potentially relevant articles as possible. We did not exclude studies published in languages other than English. We were not successful in contacting authors to clarify aspects of incomplete or selective reporting that were partially reported e.g. details on randomisation processes, allocation concealment, drop‐outs, adverse events and funding sources. </p> <p>In the AVG studies, the inclusion of the small pilot study (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> substantially affects the direction and/or magnitude of the pooled estimate for the efficacy, hospitalisation and major bleeding outcomes. This occurs because there are not many other studies or when the outcome event rate is generally low. Use of a conservative default ITT analysis has for two studies (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> meant using the worst‐case scenario. We tried to mitigate these issues by exploring the impact with sensitivity analyses. </p> </section> <section id="CD011353-sec-0110"> <h3 class="title" id="CD011353-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD011353-bbs2-0032" title="PalmerSC , DiMiccoL , RazavianM , CraigJC , RavaniP , PerkovicV , et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta‐analysis. American Journal of Kidney Diseases2013;61(1):112‐22. [MEDLINE: 23022428] ">Palmer 2013a</a> reviewed antiplatelet agents for preventing HD access failure. They concluded that antiplatelet treatment protects AVFs from thrombosis or loss of patency (6 studies, 1242 participants: RR 0.49, 95% CI 0.30 to 0.81), no GRADE certainty of evidence was reported, however more detailed information found in a complementary Cochrane review (<a href="./references#CD011353-bbs2-0033" title="PalmerSC , DiMiccoL , RazavianM , CraigJC , PerkovicV , PellegriniF , et al. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD008834.pub3] ">Palmer 2013b)</a> reveals that five of the six studies would have been classified as having a high risk of bias, the remaining study would be classified as uncertain. With the (arguably) added concern about imprecision, it would be reasonable to grade the certainty of evidence as low. Nevertheless the potential benefit of antiplatelets for AVFs means that future AVF studies should seriously consider using antiplatelet agents as an active control. </p> <p>In their updated Cochrane review on medical adjuvant treatments to increase HD vascular access patency rates, <a href="./references#CD011353-bbs2-0040" title="TannerNC , DaSilvaA . Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD002786.pub3] ">Tanner 2015</a> included two of our included studies (<a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> when evaluating fish oil interventions. The efficacy outcome they reported from the <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> paper was the risk of "one or more thrombosis events", in contrast, we reported the risk of "loss of native patency", see Table 2 of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>. The difference is that our outcome is a composite outcome ("... graft having a primary event thromboses or requiring radiological or surgical intervention to maintain patency following its creation.") that contains their outcome as a subset. The analysis they reported is what we regard as a middle‐case 1 scenario ITT analysis (2 studies, 220 participants: OR 0.24, 95% CI 0.03 to 1.95), when expressed in terms of the RR, it is equivalent to RR 0.72 (95% CI 0.16 to 1.44). They concluded that "there was insufficient evidence to determine if there was a difference in graft patency". Although they did not report a GRADE certainty of evidence, a reasonable conclusion based on their own risk of bias assessment and downgrading for inconsistency (I<sup>2</sup> = 66%) and imprecision would be that there is low certainty evidence that fish oils may slightly reduce the risk of thrombosis, and the 95% CI indicates that the intervention might make little or no difference. This is consistent with our conclusion of very low level evidence for effect on risk of LOP at 12 months (<a href="./full#CD011353-tbl-0002">summary of findings Table 2</a>. The difference in judgments is attributable to our harsher Risk of Bias appraisal. If our appraisal had been used instead, there would have been a further downgrading for risk of bias and hence the certainty of evidence judgments would have been identical regardless of the efficacy endpoint chosen. What further differentiates our review from theirs is the exclusive focus on ω‐3FA supplements and incorporation of new evidence from three studies (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990;</a><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) which also include the only large study of AVF patients. </p> <p>The systematic review of <a href="./references#CD011353-bbs2-0021" title="HeL , LiMS , LinM , ZhaoTY , GaoP . Effect of fish oil supplement in maintenance hemodialysis patients: a systematic review and meta‐analysis of published randomized controlled trials. European Journal of Clinical Pharmacology2016;72(2):129‐39. [MEDLINE: 26558899] ">He 2016</a> of ω‐3FA versus placebo in HD patients reported a largely different set of outcomes than the ones in this review. Their meta‐analysis of "arteriovenous graft events" most closely approximates our primary outcome (see Fig. 2 of <a href="./references#CD011353-bbs2-0021" title="HeL , LiMS , LinM , ZhaoTY , GaoP . Effect of fish oil supplement in maintenance hemodialysis patients: a systematic review and meta‐analysis of published randomized controlled trials. European Journal of Clinical Pharmacology2016;72(2):129‐39. [MEDLINE: 26558899] ">He 2016</a>). They included four studies; three were common to our review (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a>; <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>; <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a>. The remaining study (<a href="./references#CD011353-bbs2-0010" title="DegerSM , HungAM , EllisCD , BookerC , BianA , ChenG , et al. High dose omega‐3 fatty acid administration and skeletal muscle protein turnover in maintenance hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2016;11(7):1227‐35. [MEDLINE: 27281699] HungAM , BookerC , EllisCD , SiewED , GravesAJ , ShintaniA , et al. Omega‐3 fatty acids inhibit the up‐regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrology Dialysis Transplantation2015;30(2):266‐74. [MEDLINE: 25204316] ">Hung 2015)</a>, was excluded from our review because the event measured was graft infection and not explicitly loss of patency (see Table 4 of <a href="./references#CD011353-bbs2-0010" title="DegerSM , HungAM , EllisCD , BookerC , BianA , ChenG , et al. High dose omega‐3 fatty acid administration and skeletal muscle protein turnover in maintenance hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2016;11(7):1227‐35. [MEDLINE: 27281699] HungAM , BookerC , EllisCD , SiewED , GravesAJ , ShintaniA , et al. Omega‐3 fatty acids inhibit the up‐regulation of endothelial chemokines in maintenance hemodialysis patients. Nephrology Dialysis Transplantation2015;30(2):266‐74. [MEDLINE: 25204316] ">Hung 2015</a>). The other differences between their meta‐analysis and ours were: </p> <p> <ul id="CD011353-list-0046"> <li> <p>their analysis of <a href="./references#CD011353-bbs2-0006" title="BowdenRG , WilsonRL , DeikeE , GentileM . Fish oil supplementation lowers C‐reactive protein levels independent of triglyceride reduction in patients with end‐stage renal disease. Nutrition in Clinical Practice2009;24(4):508‐12. [MEDLINE: 19461006] ">Bowden 2009</a> used a per protocol analysis ‐ we used an ITT analysis; </p> </li> <li> <p>their analysis of <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> is slightly wrong, because they used the wrong number of control group events ‐ 7 instead of 9 (see page 186 of <a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a>); </p> </li> <li> <p>their analysis of Lok counted thrombosis events and not loss of native patency (see Table 2 of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>); </p> </li> <li> <p>they pooled a study with 6 months follow‐up <a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> with two studies of 12 months follow‐up; </p> </li> <li> <p>they used a fixed‐effect rather than a random‐effects model to pool the data, which we judged as inappropriate given the design heterogeneity ‐ differences in length of follow‐up and outcome definition; </p> </li> <li> <p>we have included two additional studies (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>; <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>). </p> </li> </ul> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011353-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011353-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011353-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 1 Loss of patency by 6 months." data-id="CD011353-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 1 Loss of patency by 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 2 Loss of patency by 12 months." data-id="CD011353-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 2 Loss of patency by 12 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 3 Loss of patency: Hazard ratio." data-id="CD011353-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 3 Loss of patency: Hazard ratio. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 4 Serious adverse events: death." data-id="CD011353-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 4 Serious adverse events: death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 5 Serious adverse events: hospitalisation." data-id="CD011353-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 5 Serious adverse events: hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 6 Serious adverse events: cardiovascular events." data-id="CD011353-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 6 Serious adverse events: cardiovascular events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 7 Serious adverse events: major bleeding." data-id="CD011353-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 7 Serious adverse events: major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 8 Adverse events: minor bleeding." data-id="CD011353-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 8 Adverse events: minor bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 9 Adverse events: gastrointestinal events." data-id="CD011353-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 9 Adverse events: gastrointestinal events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 10 Adverse events: other adverse events." data-id="CD011353-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 10 Adverse events: other adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 11 Sensitivity analysis: loss of patency by 6 months." data-id="CD011353-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 11 Sensitivity analysis: loss of patency by 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 12 Sensitivity analysis: loss of patency by 12 months." data-id="CD011353-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 12 Sensitivity analysis: loss of patency by 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 13 Sensitivity analysis: death." data-id="CD011353-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 13 Sensitivity analysis: death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 14 Sensitivity analysis: hospitalisation." data-id="CD011353-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 14 Sensitivity analysis: hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 15 Sensitivity analysis: cardiovascular events." data-id="CD011353-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 15 Sensitivity analysis: cardiovascular events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 16 Sensitivity analysis: major bleeding." data-id="CD011353-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 16 Sensitivity analysis: major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 17 Sensitivity analysis: minor bleeding." data-id="CD011353-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 17 Sensitivity analysis: minor bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 18 Sensitivity analysis: gastrointestinal events." data-id="CD011353-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 18 Sensitivity analysis: gastrointestinal events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011353-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/urn:x-wiley:14651858:media:CD011353:CD011353-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_t/tCD011353-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 19 Sensitivity analysis: other adverse events." data-id="CD011353-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 19 Sensitivity analysis: other adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/media/CDSR/CD011353/image_n/nCD011353-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011353-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Dialysis vascular access outcomes in AVF patients with ESKD<br/> <b>Setting:</b> chronic outpatient haemodialysis<br/> <b>Intervention:</b> omega‐3 fatty acids (ω‐3FA)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ω‐3FA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of patency: assessed with clinical absence of bruit or need of rescue intervention<br/> Follow up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>470 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>475 per 1,000<br/> (395 to 569) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.84 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: death<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1,000<br/> (2 to 52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.00<br/> (‐0.03 to 0.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>567 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: hospitalisation<br/> Follow up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>385 per 1,000<br/> (305 to 465) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.00<br/> (‐0.08 to 0.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>567 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events: cardiovascular events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events: major bleeding</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RD:</b> Risk difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> 95% CI is wide and consistent with both important harm or benefit </p> <p><sup>2</sup> Unclear risk of bias ‐ attrition bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011353-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> dialysis vascular access outcomes in AVG patients with ESKD<br/> <b>Setting:</b> chronic outpatient haemodialysis<br/> <b>Intervention:</b> omega‐3 fatty acids (ω‐3FA)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ω‐3FA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Loss of patency by 6 months assessed with Fistulagram or duplex ultrasonography<br/> Follow up: range 6 to 8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.91<br/> (0.36 to 2.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>41 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1,000<br/> (144 to 912) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1,000<br/> (126 to 798) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>607 per 1,000<br/> (240 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Loss of patency by 12 months assessed with angiography<br/> Follow up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RR 0.59<br/> (0.27 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>220 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>633 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>373 per 1,000<br/> (171 to 829) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>366 per 1,000<br/> (167 to 812) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1,000<br/> (203 to 983) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Serious adverse events: death<br/> Follow up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD 0.01<br/> (‐0.05 to 0.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>261 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/> (12 to 132) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1,000<br/> (0 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1,000<br/> (32 to 152) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events: hospitalisation<br/> Follow up: mean 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RD 0.08<br/> (‐0.11 to 0.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000<br/> (0 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Serious adverse events: cardiovascular events<br/> Follow up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>RD ‐0.02<br/> (‐0.11 to 0.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>261 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1,000<br/> (60 to 240) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000<br/> (0 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1,000<br/> (65 to 245) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events: major bleeding<br/> Follow up: range 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000<br/> (0 to 280) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.08<br/> (‐0.11 to 0.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RD:</b> Risk difference; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unclear risk of bias ‐ selection and attrition bias </p> <p><sup>2</sup> Point estimates favour different interventions </p> <p><sup>3</sup> 95% CI is wide and consistent with both important harm and benefit </p> <p><sup>4</sup> Point estimates are widely differing and I<sup>2</sup> &gt; 50% </p> <p><sup>5</sup> 95% CI is wide and consistent with both moderate harm and benefit </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Intention‐to‐treat (ITT) case scenarios</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>ITT Scenario</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Losses to follow‐up assumed to have events<sup>1</sup> of interest</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ω‐3FA Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control Group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>1</sup>In this review, all outcome events were bad events e.g. loss of patency, serious adverse events, non‐serious adverse events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Intention‐to‐treat (ITT) case scenarios</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intention‐to‐treat (ITT) case scenarios used in the analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Default ITT scenario used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analyses</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 2<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All except <a href="./references#CD011353-fig-0006" title="">Analysis 1.4</a> and <a href="./references#CD011353-fig-0008" title="">Analysis 1.6</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one scenario needed<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-fig-0006" title="">Analysis 1.4</a> (death); <a href="./references#CD011353-fig-0008" title="">Analysis 1.6</a> (cardiovascular event) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All except <a href="./references#CD011353-fig-0004" title="">Analysis 1.2</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Authors' modified ITT analysis<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-fig-0004" title="">Analysis 1.2</a> (loss of patency) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>1</sup>Middle‐case 2 scenario used because the middle‐case 1 scenario was identical with the best‐case scenario. </p> <p><sup>2</sup>No ITT scenario analysis was required as there was complete follow‐up and ascertainment for these two outcomes. </p> <p><sup>3</sup>Authors performed a modified ITT analysis on 536 out of 567 randomised participants, that involved imputing values for the primary outcome of AVF failure for 122 "missing data" see <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> Fig 1 and Table 2. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Intention‐to‐treat (ITT) case scenarios used in the analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reporting and extraction of AE data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of serious adverse events/adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Manner of reporting in paper</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>How outcome data values were inferred for extraction and analysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0006"> <li> <p>"One EPA patient died within 1 week of initiation of the study from an acute myocardial infarction." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </li> <li> <p>See Figure 1 of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0007"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no deaths occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have died</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0008"> <li> <p>"One patient receiving EPA developed a gastrointestinal bleed requiring hospitalization." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0009"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no hospitalisation occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0010"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have been hospitalised</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0011"> <li> <p>"The occurrences of minor and major bleeding episodes, changes in lipid status and blood pressure, hospitalizations for cardiovascular events, and death were determined. All endpoints reported were prespecified." </p> </li> </ul> <ul id="CD011353-list-0012"> <li> <p>"There was no difference in bleeding (9 events in the fish oil group vs 8 in the placebo group; P&gt;99) or other significant clinical adverse events between the 2 treatment groups." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Cardiovascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0013"> <li> <p>"One EPA patient died within 1 week of initiation of the study from an acute myocardial infarction." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> </p> </li> <li> <p>See Table 2 of <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0014"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no cardiovascular events occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0015"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have experienced a cardiovascular event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> <p> <ul id="CD011353-list-0016"> <li> <p>"Secondary outcomes included components of the primary outcome, and safety outcomes."</p> </li> </ul> <ul id="CD011353-list-0017"> <li> <p>"Adverse drug events, including bleeding events (16 [6%] vs 10 [4%]; P = .23) and gastrointestinal adverse effects (15 [5%] vs 14 [5%]; P = .86), were similar for the fish oil and placebo groups. Death occurred in 8 participants allocated to fish oil and 9 allocated to placebo (Table 3)." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis. Although it might be reasonable to assume there were no events there was too much missing data (&gt; 20% in each arm) for any ITT scenario analysis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0018"> <li> <p>"One patient receiving EPA developed a gastrointestinal bleed requiring hospitalization." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a>) </p> </li> <li> <p>"No overt bleeding episodes were observed in either group." (<a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002)</a> </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0019"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no major bleeding occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0020"> <li> <p>"There was no difference in bleeding (9 events in the fish oil group vs 8 in the placebo group; P&gt;.99)..." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from default meta‐analysis, as bleeding events were aggregated and not separately reported as major or minor </p> <p>Sensitivity analysis done included the study by assuming all were major bleeding events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis. Although it might be reasonable to assume there were no events (see Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>) there was too much missing data (&gt; 20% in each arm) for any ITT scenario analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Minor bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0021"> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct. We assumed that all the bleeding events were minor as they were not listed under the serious adverse events category </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0022"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our ITT analysis assumed no minor bleeding occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> <p> <ul id="CD011353-list-0023"> <li> <p>"One EPA patient died within 1 week of initiation of the study from an acute myocardial infarction. One patient receiving EPA developed a gastrointestinal bleed requiring hospitalization. One patient receiving placebo developed gas gangrene secondary to Clostridium perfringens which required debridement and antibiotics." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As there were only seven participants, ITT analysis assumed complete reporting of all adverse events i.e. no minor bleeding events except for the one imputed for the scenario </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0024"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this individual to have experienced a minor bleed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0025"> <li> <p>"There was no difference in bleeding (9 events in the fish oil group vs 8 in the placebo group; P&gt;.99)..." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from default meta‐analysis, as bleeding events were aggregated and not separately reported as major or minor </p> <p>Sensitivity analysis done included the study by assuming all were minor bleeding events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Gastrointestinal events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0026"> <li> <p>"A total of 5 patients in the treatment group (n‐3) and 2 in the control</p> </li> <li> <p>group (n‐6) reported gastrointestinal distress that included bloating, gas, and a “fish” aftertaste." (<a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007)</a> </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>As there were only seven participants, ITT analysis assumed complete reporting of all adverse events i.e. no gastrointestinal events except for the one imputed for the scenario analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0027"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have experienced a gastrointestinal event</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> <p> <ul id="CD011353-list-0028"> <li> <p>"There was no difference in bleeding... or other significant clinical adverse events between the 2 treatment groups." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Other adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990</a> </p> <p><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fully reported</p> <p> <ul id="CD011353-list-0029"> <li> <p>"One patient receiving placebo developed gas gangrene secondary to Clostridium perfringens which required debridement and antibiotics." (<a href="./references#CD011353-bbs2-0002" title="DiskinCJ , ThomasCE , ZellnerCP , LockS , TanjaJ . Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron1990;55(4):445‐7. [MEDLINE: 2202923] ">Diskin 1990)</a> </p> </li> <li> <p>See Table 3 of <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a>. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Direct</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] ">Bowden 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0030"> <li> <p>"During the course of this study, no adverse events occurred that were related to n‐3 or n‐6 fatty acid consumption." </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed no other adverse events occurred</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0005" title="SchmitzPG , McCloudLK , ReikesST , LeonardCL , GellensME . Prophylaxis of hemodialysis graft thrombosis with fish oil: double‐blind, randomized, prospective trial. Journal of the American Society of Nephrology2002;13(1):184‐90. [MEDLINE: 11752036] SchmitzPG , McCloudMK , LeonardCL , GellensME . Dietary supplementation with fish oil inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):1101A. SchmitzPG , TylerLD , LeonardCL , McCloudLK , GellensME . Dietary enrichment with fish oil (FO) inhibits vascular access thrombosis in PTFE grafts [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):171A. [CENTRAL: CN‐00447632] ">Schmitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indirect</p> <p> <ul id="CD011353-list-0031"> <li> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis assumed this participant to have experienced some other adverse events.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured but partially reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study excluded from meta‐analysis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reporting and extraction of AE data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study drop‐outs and analysis totals (Bowden 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drop‐outs from authors' analysis (see </b><a href="./references#CD011353-bbs2-0001" title="BowdenRG , WilsonRL , GentileM , OunpraseuthS , MooreP , LeutholtzBC . Effects of omega‐3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts. Journal of Renal Nutrition2007;17(2):126‐31. [MEDLINE: 17321952] "><b>Bowden 2007</b> </a><b> Table 1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for analysis drop‐out</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (14 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"In all, 2 patients from the placebo group and 3 patients from the n‐3 group completed the study but were not included in the analysis because of noncompliance..." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (15 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ITT‐ intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study drop‐outs and analysis totals (Bowden 2007)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study drop‐outs and analysis totals (Diskin 1990)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss to follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for loss to follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"One EPA patient died within 1 week of initiation of the study</p> <p>from an acute myocardial infarction."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study drop‐outs and analysis totals (Diskin 1990)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Study drop‐outs and analysis totals (FAVOURED 2009)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drop‐outs from authors' analysis (see </b><a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] "><b>FAVOURED 2009</b> </a><b> Table 2 and 3)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for analysis drop‐outs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcomes: 14 (270 participants analysed)</p> <p>Safety outcomes: 0 (284 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcome: 270</p> <p>Safety outcomes: 284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>See <a href="./references#CD011353-bbs2-0003" title="IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 034]. Nephrology2010;15(Suppl 4):35. IrishA . Baseline characteristics of the patients participating in the FAVOURED trial [abstract]. Nephrology2014;19(Suppl 4):19. [EMBASE: 71587790] IrishA , DograG , MoriT , BellerE , HeritierS , HawleyC , et al. Preventing AVF thrombosis: the rationale and design of the Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology2009;10:1. [MEDLINE: 19159453] IrishA , ViecelliA , HawleyC , HooiL , PascoeE , Paul‐BrentP , et al. Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis‐a randomized controlled trial [abstract]. Nephrology2016;21(Suppl 2):47. [EMBASE: 612312804] IrishA , FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology2009;14(Suppl 1):A45. [CENTRAL: CN‐00756870] IrishAB . The omega‐3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study: a randomised placebo‐controlled trial [abstract no: HI‐OR08]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):B2‐3. IrishAB , ViecelliAK , HawleyCM , HooiLS , PascoeEM , Paul‐BrentPA , et al. Effect of fish oil supplementation and aspirin use on arteriovenous fistula failure in patients requiring hemodialysis: a randomized clinical trial. JAMA Internal Medicine2017;177(2):184‐93. [MEDLINE: 28055065] ViecelliA , PascoeE , HawleyC , PolkinghorneK , MoriT , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis‐post hoc analysis of the FAVOURED study [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii65. [EMBASE: 617291475] ViecelliA , PascoeE , PolkinghorneK , DarssanD , MoriT , HawleyC , et al. Regional differences in arteriovenous fistula failure observed in the FAVOURED trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii335. [EMBASE: 617291178] ViecelliA , PascoeE , PolkinghorneK , MoriT , HawleyC , JohnsonD , et al. Effects of fish oil supplementation and aspirin use on need for arteriovenous fistula interventions and central venous catheters in patients requiring haemodialysis [abstract]. Nephrology Dialysis Transplantation2018;33(Suppl 1):i227. [EMBASE: 622605265] ViecelliA , PascoeE , PolkinghorneK , Paul‐BrentP , DarssanD , HooiL , et al. A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial [abstract]. Nephrology2016;21(Suppl 2):115‐6. [EMBASE: 612312707] ViecelliAK , PascoeE , PolkinghorneKR , HawleyC , Paul‐BrentPA , BadveSV , et al. The Omega‐3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post‐initiation trial modifications. BMC Nephrology2015;16:89. [MEDLINE: 26116581] ViecelliAK , PascoeEM , HawleyCM , PolkinghorneKR , MoriTA , JohnsonDW , et al. Effects of fish oil supplementation and aspirin use on arteriovenous fistula patency, need for interventions and dialysis suitability in patients requiring haemodialysis ‐ Post hoc analysis of the FAVOURED study [abstract]. Nephrology2017;22(Suppl 3):12. [EMBASE: 618236182] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2016;21(3):217‐28. [MEDLINE: 26205903] ViecelliAK , PascoeEM , PolkinghorneKR , HawleyCM , Paul‐BrentPA , BadveSV , et al. Updates on baseline characteristics of the omega‐3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology2017;22(10):823‐4. [MEDLINE: 27188542] ">FAVOURED 2009</a> Fig 1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcomes: 17 (266 participants analysed)</p> <p>Safety outcomes: 0 (283 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy outcome: 266</p> <p>Safety outcomes: 283</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Study drop‐outs and analysis totals (FAVOURED 2009)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Study drop‐outs and analysis totals (FISH 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drop‐outs from authors' analysis (see </b><a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. "><b>FISH 2007</b> </a><b> Figure 1)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for analysis drop‐outs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (99 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>See <a href="./references#CD011353-bbs2-0004" title="LokCE , AllonM , DonnellyS , DorvalM , HemmelgarnB , MoistL , et al. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clinical Trials2007;4(4):357‐67. [MEDLINE: 17848497] LokCE , MoistL , HemmelgarnBR , TonelliM , VazquezMA , DorvalM , et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA2012;307(17):1809‐16. [MEDLINE: 22550196] LokCE , MoistLM , HemmelgarnB , TonelliM , AllonM , StanleyK . The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study [abstract no: LB‐OR01]. Journal of the American Society of Nephrology2011;22(Abstracts):1B. ">FISH 2007</a> Fig 1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (97 participants analysed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Study drop‐outs and analysis totals (FISH 2007)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011353-tbl-0010"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Study drop‐outs and analysis totals (Schmitz 2002)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss to follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. analysed in our ITT scenarios</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for loss to follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ω‐3FA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>"One patient in the fish oil‐treated group was lost to follow‐up monitoring at 7 mo."</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ITT ‐ intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Study drop‐outs and analysis totals (Schmitz 2002)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/full#CD011353-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011353-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omega‐3 fatty acids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Loss of patency by 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.36, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Loss of patency by 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 AVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.27, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Loss of patency: Hazard ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events: death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 AVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.05, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events: hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.06, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 AVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.08, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.11, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events: cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.11, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events: major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 AVG (excluding FISH 2007)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.11, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 AVG (including FISH 2007)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events: minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 AVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 AVG (excluding FISH 2007)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.07, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 AVG (including FISH 2007)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events: gastrointestinal events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.05, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 AVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.03, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.07, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 AVF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 AVG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Sensitivity analysis: loss of patency by 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.15, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.11, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.35, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.26, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.15, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Sensitivity analysis: loss of patency by 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.18, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.14, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.25, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.22, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Sensitivity analysis: death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.13, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.05, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.06, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.02, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.06, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sensitivity analysis: hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.16, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.05, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.09, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Sensitivity analysis: cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.27, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.10, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.12, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.02, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.12, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Sensitivity analysis: major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.16, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.05, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.09, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sensitivity analysis: minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.15, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.09, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.06, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.09, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Sensitivity analysis: gastrointestinal events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.04, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.09, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.15, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Sensitivity analysis: other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.20, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Middle‐case 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Middle‐case 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.06, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Worst‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.02, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 Per protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.10, 0.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omega‐3 fatty acids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011353.pub2/references#CD011353-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011353.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011353-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011353-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011353-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD011353-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011353-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011353-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011353-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011353-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011353\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011353\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011353\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011353\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011353\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011353.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011353.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011353.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011353.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011353.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719837972"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011353.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719837975"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011353.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df281bc90937f',t:'MTc0MDcxOTgzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 